1549 related articles for article (PubMed ID: 30350010)
1.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
2.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
3.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
4.
Deandreis D; Guarneri A; Ceci F; Lillaz B; Bartoncini S; Oderda M; Nicolotti DG; Pilati E; Passera R; Zitella A; Bellò M; Parise R; Carlevato R; Ricardi U; Gontero P
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2804-2815. PubMed ID: 32314028
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
7.
Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological predictors of positive
Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
[TBL] [Abstract][Full Text] [Related]
9. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Ceci F; Uprimny C; Nilica B; Geraldo L; Kendler D; Kroiss A; Bektic J; Horninger W; Lukas P; Decristoforo C; Castellucci P; Fanti S; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1284-94. PubMed ID: 25975367
[TBL] [Abstract][Full Text] [Related]
10. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
11.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
12. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
[TBL] [Abstract][Full Text] [Related]
13. Interobserver variability, detection rate, and lesion patterns of
Miksch J; Bottke D; Krohn T; Thamm R; Bartkowiak D; Solbach C; Bolenz C; Beer M; Wiegel T; Beer AJ; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
15. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
16. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M
J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990
[TBL] [Abstract][Full Text] [Related]
19. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
20. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]